Evidence map›Paper›PMID 42587156›Full record

ArticleNature2026

Biomarkers of nivolumab benefit in resectable non-small cell lung cancer.

Tina Cascone, Mark M Awad, Jonathan D Spicer, Jie He, Shun Lu, Fumihiro Tanaka, Robin Cornelissen, Lubos B Petruzelka, Yang Gao, Jean-Louis Pujol and 21 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04025879 (A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04025879 phase3active not recruitingnot on this map

A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer

TypeinterventionalSponsorBristol-Myers SquibbRan2019 to 2027Enrolled461ConditionsCarcinoma, Non-Small-Cell LungArmsNivolumab, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Advances in mutant characterization for detecting causal mutations in crop plants.TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Tina CasconeThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. tcascone@mdanderson.org.ORCID http://orcid.org/0000-0003-3008-5407
Mark M AwadMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Jonathan D SpicerMcGill University Health Centre, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0003-2708-1309
Jie HeNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID http://orcid.org/0000-0001-6961-8421
Shun LuShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Fumihiro TanakaUniversity of Occupational and Environmental Health, Kitakyushu, Japan.
Robin CornelissenErasmus MC Cancer Institute, Rotterdam, The Netherlands.
Lubos B PetruzelkaCharles University, Prague, Czech Republic.
Yang GaoXiangya Hospital, Central South University, Changsha, China.
Jean-Louis PujolMontpellier Regional University Hospital, Montpellier, France.
Hiroyuki ItoKanagawa Cancer Center, Yokohama, Japan.
Ludmila de Oliveira Muniz KochHospital Israelita Albert Einstein, Sao Paulo, Brazil.
Tudor-Eliade CiuleanuProf. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca, Romania.ORCID http://orcid.org/0009-0006-5351-4234
Lin WuHunan Cancer Hospital, Changsha, China.
Sabine BohnetUniversity Medical Center Schleswig-Holstein, Lubeck, Germany.
Yasutaka WatanabeSaitama Cancer Center, Saitama, Japan.ORCID http://orcid.org/0000-0002-3679-4864
Janis M TaubeJohns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-8273-4395
Julie Stein DeutschJohns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-8040-5205
Cinthya Coronado ErdmannBristol Myers Squibb, Boudry, Switzerland.
Stephanie Meadows-ShropshireBristol Myers Squibb, Princeton, NJ, USA.
Jaclyn NeelyBristol Myers Squibb, Princeton, NJ, USA.ORCID http://orcid.org/0000-0001-7137-3953
Virginia IpBristol Myers Squibb, Princeton, NJ, USA.ORCID http://orcid.org/0009-0001-1448-6633
Yu-Han HungBristol Myers Squibb, Princeton, NJ, USA.
Padma SathyanarayanaBristol Myers Squibb, Princeton, NJ, USA.
Sumeena BhatiaBristol Myers Squibb, Princeton, NJ, USA.
Katherine ChuBristol Myers Squibb, Princeton, NJ, USA.
Steven I BlumBristol Myers Squibb, Princeton, NJ, USA.
Stefano LucheriniBristol Myers Squibb, Uxbridge, UK.
Nathanial EddyBristol Myers Squibb, Princeton, NJ, USA.
Akshay YadavBristol Myers Squibb, Hyderabad, India.
Mariano ProvencioHospital Universitario Puerta de Hierro, Madrid, Spain.ORCID http://orcid.org/0000-0001-6315-7919

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Perioperative nivolumab significantly improved event-free survival (EFS) compared with placebo in patients with resectable non-small cell lung cancer (NSCLC) in the CheckMate 77T study (ClinicalTrials.gov NCT04025879 )

Identifiers

PMID42587156

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.